00775 CKLIFE SCIENCES
- 0.450
- 0.0000.00%
CKLIFE SCIENCES News
長江生命科技：二零二三年年報
Changes in Hong Kong stocks | Changjiang Life Technology (00775.HK) rises by nearly 30%. The company will display cancer vaccine research data and cancer vaccine model research cooperation data
Changjiang Life Science (00775.HK) rose by nearly 30%. As of press release, it had risen 21.88% to HK$0.39, with a turnover of HK$13.1371 million.
The Hong Kong stock of Li Ka-shing's Changjiang Life Science and Technology rose nearly 30%. AI helped advance cancer vaccine research. The company will present cancer vaccine research data at the AACR annual meeting.
The Hong Kong stock of Li Ka-shing's Changjiang Life Science and Technology rose nearly 30%. AI helped advance cancer vaccine research. The company will present cancer vaccine research data at the AACR annual meeting.
Changjiang Life Science (00775.HK): New data from preclinical research on KRAS and PD-L1 research cancer vaccines will be exhibited at the AACR 2024 annual meeting
Gelonghui, April 5, 丨 Changjiang Life Technology (00775.HK) announced that the company will present two sets of new pre-clinical research data on rat sarcoma virus oncogene (KRAS) and cell-mediated death-ligand 1 (PD-L1) research cancer vaccines at the 2024 annual meeting of the American Association for Cancer Research (AACR) to be held in San Diego, California, USA. According to the disclosure, KRAS protein is commonly mutated in various cancers and is a key regulator of cell growth and survival, driving tumor growth by promoting uncontrolled cell reproduction and resistance to treatment. PD-L1 protein is
Announcement Highlights: Xiaomi Q4's adjusted net profit increased 236.1% year on year; Xiaopeng Motor Q4's adjusted net loss decreased by 19.9% year on year
Li Ning's revenue in 2023 was 27.598 billion yuan, an increase of 7.0%; China Unicom's profit due to equity holders in 2023 was 18.7 billion yuan, an increase of 11.8% over the previous year.
Changjiang Life Science (00775.HK): Profit attributable to shareholders in 2023 HK$17.25 million
Gelonghui, March 19, 丨 Changjiang Life Technology (00775.HK) announced that for the year ended December 31, 2023, it achieved revenue of HK$5.323 billion, up 1% year on year; recorded profit attributable to shareholders of HK$17.25 million, down 87% year on year, with a basic profit of 0.18 cents per share. The business environment has been turbulent for the past three years. In 2021, as the coronavirus epidemic began to recede, the company promptly raised prices, streamlined operations and improved efficiency to mitigate the impact of inflation, labor shortages and supply chain disruptions. When central banks around the world raised interest rates sharply in 2022 to curb inflation
CKLIFE SCIENCES: ANNUAL RESULTS FOR 2023
Changjiang Life Science (00775.HK) held a board meeting on March 19 to approve publication of annual results
Gelonghui, March 7, 丨 Changjiang Life Technology (00775.HK) announced that the company will hold a board meeting in Hong Kong on March 19, 2024 (Tuesday) to (among others) approve the publication of the results of the company and its subsidiaries for the financial year ended 31 December 2023 and consider payment of a final dividend.
Express News | Shenzhen Stock Exchange: Changes to the list of Hong Kong Stock Exchange securities under the Shenzhen-Hong Kong Stock Connect
Changjiang Life Science (00775.HK) expects profit attributable to shareholders for the year to be drastically reduced
Gelonghui, Feb. 21丨Changjiang Life Technology (00775.HK) announced that the company expects profit attributable to shareholders for the year ended December 31, 2023 to be drastically reduced compared to the previous year. This reduction is expected to exceed those reported by the company in its 2023 interim report and is due to the impact of a sharp increase in financial costs on the Group's overall profit in the reporting year. The Group's operations remained stable during the reporting year and as of the date of this announcement.
CKLIFE SCIENCES: INSIDE INFORMATION ANNOUNCEMENT
Opinion | Hang Seng Index quarterly inspection results announced, which companies are expected to become the Hong Kong Stock Exchange Index?
After the market on February 16, 2024, Hang Seng Indices announced the results of its regular semi-annual index adjustments (the review ends on December 31, 2023, and is generally announced within 8 weeks after the inspection date). The scope of this adjustment covers the main flagship indices of Hong Kong stocks, such as the Hang Seng, the State-owned Enterprises Index, and the Hang Seng Technology Index; in addition, the Hang Seng Composite Index, which directly determines the scope of investment in Hong Kong Stock Connect, has also been adjusted.
Exploring a New Model for Cancer Prognosis Risk Prediction: Jingtai Technology and Changjiang Life Technology Reach R&D Cooperation
(Pharmaceutical News, November 6, 2023) Jingtai Technology, which empowers life science research with AI+ robots, announced that it has signed a new R&D collaboration with CK Life Sciences (CK Life Sciences). The two companies will combine artificial intelligence (AI) algorithms with clinical diagnosis and biomarker data from desensitized cancer patients and healthy people to jointly explore and develop molecular diagnostic models for cancer prognosis risk prediction based on miRNA. Using AI and machine learning, this collaboration hopes to develop more advanced and intelligent solutions for the development and modeling of multi-dimensional biological data, the discovery of cancer disease markers, and the risk of recurrence in patients after surgery.
CK Life Sciences to Present Preclinical Study of Cancer Vaccines at US Immunotherapy Conference
CK Life Sciences (HKG:0775) will present preclinical data of its investigational dual-antigen cancer vaccines at the 2023 Society for Immunotherapy of Cancer Annual Meeting in California on Nov. 4. Th
Changjiang Life Technology (00775.HK) will present pre-clinical research data on PRAME and PD-L1 double antigen cancer vaccines at the annual meeting of the Society of Cancer Immunotherapy
Gelonghui November 1 | Changjiang Life Technology (00775.HK) announced that the company will present pre-clinical research data on the development of a dual antigen cancer vaccine targeting melanoma priority antigen (PRAME) and cytostatic death-ligand 1 (PD-L1) at the annual meeting of the Society of Cancer Immunotherapy to be held in San Diego, California, USA on November 4, 2023. The cancer vaccine in this preclinical study contains PRAME and PD-L1 antigen sequences to induce an anti-cancer immune response. PRAME is a cancer antigen commonly found in many different types of cancer, and various carcinogens
CK Life Sciences International's Profit Slumps 43% in H1; Shares Down 3%
CK Life Sciences International (Holdings) (HKG:0775) booked a profit attributable to shareholders of HK$36.9 million for the first half, slumping 43% from HK$65.1 million in the prior year. Earnings p
CKLIFE SCIENCES: Interim Report 2023
Changes in Hong Kong stocks | Changjiang Life Technology (00775) fell more than 5%, medium-term return profit fell 43.32% year on year
The Zhitong Finance App learned that Changjiang Life Technology (00775) fell more than 5%. As of press release, it fell 3.8% to HK$0.76, with a turnover of HK$3.4895 million. According to the news, Changjiang Life Technology announced its 2023 interim results yesterday, with revenue of about HK$2,579 billion, up 1.52% year on year; profit attributable to shareholders of HK$369.12 million, down 43.32% year on year; profit of HK0.38 cents per share. The announcement said that the overall profit for the first half of 2023 was heavily pressured by high financial costs caused by interest rate hikes.
Changjiang Life Science: Net profit attributable to shareholders fell 43% year-on-year in the first half of the year
On August 1, GLONGHUI | Changjiang Life Technology (0775.HK) announced that in the first half of 2023, the company's unaudited shareholders should account for about HK$37 million in net profit, down 43% from the same period last year.
CKLIFE SCIENCES: Announcement - Interim Results for 2023
Analysis
Price Target
No Data
